Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations

The present article represents the 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult.

[1]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[2]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[3]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[4]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[5]  Steven Hawken,et al.  Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .

[6]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[7]  Ralph B D'Agostino,et al.  Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands , 2004, BMJ : British Medical Journal.

[8]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[9]  Mary Cushman,et al.  Practice Guidelines : Emerging Biomarkers for Primary Prevention of Cardiovascular Disease , 2009 .

[10]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[11]  D. Nieman,et al.  Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates , 2010 .

[12]  R. Califf,et al.  A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22 , 2006, Circulation.

[13]  Mark A. Hlatky,et al.  ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring By Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain , 2007 .

[14]  A. Kastrati,et al.  Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial , 2004, Circulation.

[15]  Winfried März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005 .

[16]  J. Després,et al.  Abdominal obesity and metabolic syndrome , 2006, Nature.

[17]  A. Gotto,et al.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2007, The New England journal of medicine.

[18]  N. Paynter,et al.  C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men , 2008, Circulation.

[19]  A. Zwinderman,et al.  Chapter Role of the apolipoprotein B / A-I ratio in cardiovascular risk assessment A case-control analysis in EPIC-Norfolk , 2009 .

[20]  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[21]  N. Paul,et al.  Perioperative β-Blockers : Use With Caution Perioperative β Blockers in Patients Having Non-Cardiac Surgery : A Meta-Analysis , 2010 .

[22]  J Thomas Bigger,et al.  Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdiscip , 2008, Circulation.

[23]  D. Waters,et al.  Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. , 1995, Current opinion in lipidology.

[24]  Charles E. McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[25]  M. Ward.  Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[26]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[27]  W. Howard.  Class of Antiretroviral Drugs and the Risk of Myocardial Infarction , 2008 .

[28]  N. Poulter,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial☆ , 2003 .

[29]  R. Kloner,et al.  To drink or not to drink? That is the question. , 2007, Circulation.

[30]  Jeffrey L. Anderson,et al.  Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. , 2008, The American journal of cardiology.

[31]  S. Grundy,et al.  Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). , 2008, The American journal of cardiology.

[32]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[33]  Paul M. Ridker,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[34]  B M Psaty,et al.  Family history as a risk factor for primary cardiac arrest. , 1998, Circulation.

[35]  G. Bárbaro,et al.  Metabolic syndrome associated with HIV and highly active antiretroviral therapy , 2009, Current diabetes reports.

[36]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[37]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[38]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[39]  B. G. Brown,et al.  Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. , 2008, The American journal of cardiology.

[40]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[41]  R. Califf,et al.  Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). , 2007, The American journal of cardiology.

[42]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[43]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[44]  Paul M. Ridker,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003 .

[45]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[46]  Robert A. Kloner,et al.  To Drink or Not to Drink? That Is the Question , 2007 .

[47]  Samin K. Sharma,et al.  Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70 mg/dl. , 2009, The American journal of cardiology.

[48]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[49]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[50]  A. A. Liakishev.  [Homocysteine lowering with folic acid and B vitamins in vascular disease]. , 2006, Kardiologiia.

[51]  C. Bernstein,et al.  The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[52]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[53]  B. Tom,et al.  Cardiovascular morbidity in psoriatic arthritis , 2008, Annals of the rheumatic diseases.

[54]  B. J. Gersh.  Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2008 .

[55]  H. Sloan,et al.  Ankle-brachial index. Calculating your patient's vascular risks. , 1999, Nursing.

[56]  Peter W. Macfarlane,et al.  Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia , 2004 .

[57]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[58]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[59]  R. Krauss,et al.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel , 2006, Journal of internal medicine.

[60]  R. Sandler,et al.  Inflammatory Bowel Disease Is Not a Risk Factor for Cardiovascular Disease Mortality: Results from a Systematic Review and Meta-Analysis , 2007, The American Journal of Gastroenterology.

[61]  P. Greenland,et al.  Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. , 2003, The New England journal of medicine.

[62]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[63]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) , 2007 .

[64]  M. Ward,et al.  Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[65]  Christopher B. Kendall,et al.  Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[66]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[67]  Z. Awan,et al.  Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). , 2008, The American journal of cardiology.

[68]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.

[69]  N. Frasure-smith,et al.  Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. , 2007, JAMA.

[70]  R. McPherson,et al.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. , 2006, The Canadian journal of cardiology.

[71]  Børge G Nordestgaard,et al.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[72]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[73]  D. Lloyd‐Jones.  Short-term versus long-term risk for coronary artery disease: implications for lipid guidelines , 2006, Current opinion in lipidology.

[74]  Lawrence Joseph,et al.  Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. , 2007, Archives of internal medicine.

[75]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[76]  Nikolaus Marx,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.

[77]  Jiang He,et al.  Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. , 2006, The American journal of medicine.

[78]  M. King,et al.  High rates of the metabolic syndrome in a First Nations Community in western Canada: prevalence and determinants in adults and children. , 2006, International journal of circumpolar health.

[79]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[80]  A Hofman,et al.  Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. , 2008, JAMA.

[81]  Peter T Katzmarzyk,et al.  Prevalence of class I, II and III obesity in Canada , 2006, Canadian Medical Association Journal.

[82]  S. Yusuf,et al.  Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). , 2000, Indian heart journal.

[83]  W. Howard,et al.  Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis , 2008 .

[84]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .